Skinvisible, Inc. (SKVI) Licensee Launches First Prescription Product in the USA
7/18/2011 10:00:50 AM
LAS VEGAS, July 18, 2011 (GLOBE NEWSWIRE) -- Skinvisible Pharmaceuticals, Inc. (OTCQB:SKVI) is pleased to announce that its licensee, Women's Choice Pharmaceuticals LLC, a specialty pharmaceutical company based in Gilbert, Arizona, has launched ProCort®, Skinvisible's first prescription product in the United States. ProCort® is a topical treatment for hemorrhoids formulated with Skinvisible's patented polymer delivery system Invisicare®. Invisicare enhances the delivery of active ingredients by controlling the release and provides superior binding properties. ProCort® is made of a combination of hydrocortisone acetate and pramoxine hydrochloride. ProCort®, launched this week, is a prescription product focused on the women's health market.
comments powered by